11:06am ET
Investing
Coronavirus Stocks See Rising Tide in Short Interest
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected coronavirus stocks increased.
REGN Coverage Page 7
8:54am ET
Investing
10 Very Strong Stocks Thriving in a Very Crummy Stock Market
These 10 stocks have incredibly strong stock charts and strong performance despite the crummy market conditions that have been seen so far in 2020.
9:10am ET
Investing
Top Analyst Upgrades and Downgrades: Casper, CME, Deere, Disney, Domino’s, Home Depot, Nike, RealReal, Salesforce, SolarEdge, Sunrun and More
Wednesday's top analyst upgrades, downgrades and initiations included Casper Sleep, CME, Deere, Domino's Pizza, Home Depot, Nike, RealReal, Salesforce.com, SolarEdge Technologies, Sunrun and Walt Disney.
9:05am ET
Investing
Top Analyst Upgrades and Downgrades: Aurora Cannabis, Biogen, Micron, Nio, Nvidia, Palo Alto, Tandem Diabetes, Tesla and More
Tuesday's top analyst upgrades, downgrades and initiations included Aurora Cannabis, Biogen, EverQuote, Micron Technology, Nio, Nvidia, Palo Alto Networks, Tandem Diabetes Care, Tesla and Wix.com.
1:35pm ET
Health and Healthcare
How Earnings Will Dictate Biotech Sector’s Fate in 2020
Why Credit Suisse believes that this round of quarterly biotech earnings could prove to be a catalyst for 2020.
9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron, Sarpeta and More
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
10:40am ET
Investing
10 Large-Cap Stocks Up 1000% to 4000% Over the Past Decade
24/7 Wall St. has identified 10 stocks that have risen 1,000% or more since the last trading day of 2009.
9:15am ET
Investing
Top Analyst Upgrades and Downgrades: Albermarle, Amgen, Applied Materials, Biogen, CRISPR, CrowdStrike, CSX, Kroger, Slack, Teva, Xerox and More
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Altice, CenturyLink, Cigna, Disney, Emerson, Foot Locker, Groupon, Lululemon, Nike, State Street and More
Wednesday's top analyst upgrades, downgrades and initiations included Altice USA, CenturyLink, Cigna, Emerson Electric, Foot Locker, Groupon, Lululemon Athletica, Nike, State Street and Walt Disney.
7:25am ET
Health and Healthcare
Top Baird Health Care and Biotech Picks Have Massive Upside Potential
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
1:05pm ET
Investing
Oil & Gas, Apparel, Pharma Vying for S&P 500’s Worst Group of 2019
Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas, 10 tied mostly to retailing of apparel and accessories, and six are…
4:45pm ET
Health and Healthcare
Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
8:54am ET
Investing
Top Analyst Upgrades and Downgrades: Array Bio, Bank of America, Oracle, Pinterest, RingCentral, Snap, SunPower, Twilio, Xilinx and More
Stocks were indicated to open higher on Tuesday after a small gain in the Dow and S&P 500 on Monday. It may be the summer, but investors need to be considering how…
12:55pm ET
Health and Healthcare
Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how…
11:10am ET
Health and Healthcare
Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.